Skip to main content

Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & Diabetic Ketoacidosis (DKA) and Use in Type 1 Diabetes Mellitus (T1DM)

    Basic Details
    Status
    Ongoing
    Last Updated
    Tuesday, August 5, 2025
    Original Posting Date
    Health Outcome(s)
    diabetic ketoacidosis (DKA)
    use in type 1 diabetes mellitus (T1DM)
    Purpose
    Drug and Outcome Analysis
    Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
    No
    Study Summary

    In response to clinical trials showing an increased risk of diabetic ketoacidosis (DKA) with sotagliflozin in type 1 diabetes mellitus (T1DM), the FDA assessed off-label use of sodium-glucose co-transporter 2 (SGLT2) inhibitors (approved for use in type 2 diabetes mellitus) and real-world rates of DKA when used in patients with T1DM. Elevated rates of DKA with off label SGLT2 inhibitor use among patients with T1DM were seen compared to clinical trials. These findings were presented at the January 17, 2019 Advisory Committee meeting for sotagliflozin, and this helped inform the committee member discussion on the benefit-risk assessment.